Stock AnalizMedline (MDLN) earnings for the quarter ended September 2026: EPS beats estimates
Medline reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at $0.44 against the analysts’ average forecast of $0.35, a beat of 26.7%.
Revenue for the quarter was $7.86 billion, up 10.4% from $7.12 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 16.6% on the first trading day after the report.
The last four quarters
Medline has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.44 | $0.35 | +26.7% | +10% | +16.6% |
| Jun 2026 | $0.50 | $0.32 | +55.8% | +12% | −17.9% |
| Mar 2026 | $0.33 | $0.29 | +12.2% | +11% | −7.6% |
| Dec 2025 | $0.31 | $0.24 | +30.0% | — | −2.2% |
What comes next
Analysts expect EPS of $0.39 for the next quarter on average and $1.56 for the fiscal year ending December 31, 2026.
The average analyst price target is $45.35, 15% above the current price of $39.47.
Valuation and score
Medline scores 1.0 out of 5 overall on Stock Analiz (weak), trades at a trailing P/E of about 89.7, and its intrinsic value under moderate assumptions is about 48% below the current market value. Full Medline analysis with 10 years of financials
Frequently asked questions
What was Medline’s EPS for the quarter ended September 2026?
$0.44 adjusted per share, against an analyst consensus of $0.35.
How much revenue did Medline report?
$7.86 billion, up 10.4% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.